Is that the short interest as of the close on the 13th? That day was the most volume we have seen since the 3s (I think).
If those are the levels as of 3/13, it is interesting since most of the move from the lows was made by that date.
Ri - can you please comment on this? I for one like/appreciate your analysis. I also only buy and hold stock and I have had ampe for over 2 years. When will the shorts flush out?
Data for short interest is out for 3/13. AMPE short interest increased to 10.4 million shares from 10.3 shares short at 2/27. 21% of AMPE float was still short at 3/13 not including any nakeds. When will they cover? I was expecting to see a decrease witht he pick up in price and volume in March. Can't be any shorts with gains at these levels.
Oh man...Up 150% in ten weeks...Really tough to be you these days Mr. Bill.
How did that goat study conclude bud, did the followup interviews show efficacy?
STRUT (N=40, wk 20):
WOMAC A: The primary endpoint that is required for FDA approval, WOMAC A pain score, improved by 64% from baseline to 20 weeks. Ampion improved by -1.41 (0.81) compared to saline vehicle control which improved by -0.85 (0.64), p=0.0231.
SPRING (20 wk, KL3 and KL4, Oppenheimer presentation, CI's est. graphically):
WOMAC A: -0.99 (-0.90 to -1.15) vs 0.-65 (-0.52 to -0.95) p=0.005
WOMAC C: -0.85 (-0.72 to -1.1) vs -0.58 (-0.40 to -0.78) p=0.04 (CI's overlap)
3x drug = 42% improvement in pain relief over single dose
3x saline = 31% improvement in pain relief over single dose
The accepted Minimal Clinically Important Improvement= 41% (PLoS One Ampion publication)
1) If this repeats for STRIDE, then it may be concluded that there is clinical benefit for triple vs single injection therapy.
2)The p value of drug vs saline for the critical WOMAC A difference is 40x's worse in triple vs single, but still acceptable (less than 0.05), due probably in part to saline's increase in pain relief when given MI. With 8-times the number of patients in STRIDE, the key concern is that the separation between Ampion and Saline doesn't decline. The response rate differences do show that the drug is more effective than saline, and that was convincing. It's not clear that the FDA would accept that criteria since the primary endpoint is WOMAC A.
Naw, Mr. Bill likes the everpresent stem cell therapy now, he's moved beyond herbal remedies straight to stem cells.
Glad you said something, thought it was just me. Looks like the link is broken. It is RI66's worst nightmare!
Sentiment: Strong Buy
That is because you have no intellect, class, depth, or understanding of facts,......you must ignore those that have these traits..... as shallow men will.